Yes, I believe dosage, delivery, timing & many other factors are now being explored vs the one size fits all approach in the past.
I think this could pose a problem at present if we were to start the inflammation trial. I think it may offer the most value where the population is concerned & address many more unmet needs. I do believe they need to learn more before they start the trial.
As much as I would like to see the trial progressing much faster, I do believe the present course is the most certain pathway to approval.